Arcus Biosciences (RCUS) Financials

$8.98 -0.53 (-5.57%)

Closing price 03:59 PM Eastern

Extended Trading

$9.01 +0.03 (+0.33%)

As of 07:24 PM Eastern

Annual Income Statements for Arcus Biosciences

This table shows Arcus Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Income / (Loss) Attributable to Common Shareholders	-283	-307	-267	53	-123	-85	-50	-53	-18
Consolidated Net Income / (Loss)	-283	-307	-267	53	-123	-85	-50	-53	-18
Net Income / (Loss) Continuing Operations	-283	-307	-267	53	-123	-85	-50	-53	-18
Total Pre-Tax Income	-282	-301	-266	55	-123	-85	-50	-53	-18
Total Operating Income	-330	-340	-280	54	-124	-89	-55	-53	-18
Total Gross Profit	258	117	112	383	78	15	8.35	1.41	0.00
Total Revenue	258	117	112	383	78	15	8.35	1.41	0.00
Operating Revenue	258	117	112	383	78	15	8.35	1.41	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	588	457	392	329	202	104	63	55	18
Selling, General & Admin Expense	120	117	104	72	43	25	14	7.64	3.94
Research & Development Expense	448	340	288	257	159	78	50	47	14
Impairment Charge	20	-	-	-	-	-	-	-	-
Total Other Income / (Expense), net	48	39	14	1.00	1.00	4.00	5.27	0.36	0.21
Interest Expense	4.00	2.00	2.00	0.00	0.00	-	-	-	-
Interest & Investment Income	52	-	-	-	-	-1.20	0.34	-0.42	0.21
Income Tax Expense	1.00	6.00	1.00	2.00	0.00	0.00	-	-	-
Basic Earnings per Share	($3.14)	($4.15)	($3.71)	-	-	-	-	-	($20.80)
Weighted Average Basic Shares Outstanding	90.10M	74M	72M	69.30M	54.80M	43.83M	34.62M	1.83M	863.98K
Diluted Earnings per Share	($3.14)	($4.15)	($3.71)	-	-	-	-	-	($20.80)
Weighted Average Diluted Shares Outstanding	90.10M	74M	72M	74M	54.80M	43.83M	34.62M	1.83M	863.98K
Weighted Average Basic & Diluted Shares Outstanding	105.84M	90.86M	73.01M	71.06M	54.79M	43.83M	34.62M	1.83M	863.98K

This table shows Arcus Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-112	-94	-92	-93	-4.00	-81	-71	-75	-80	-67	-65
Consolidated Net Income / (Loss)	-112	-94	-92	-93	-4.00	-81	-71	-75	-80	-67	-65
Net Income / (Loss) Continuing Operations	-112	-94	-92	-93	-4.00	-81	-71	-75	-80	-67	-65
Total Pre-Tax Income	-112	-93	-92	-93	-4.00	-80	-69	-74	-78	-67	-65
Total Operating Income	-122	-103	-105	-106	-16	-91	-80	-83	-86	-74	-70
Total Gross Profit	28	26	48	39	145	31	32	29	25	34	33
Total Revenue	28	26	48	39	145	31	32	29	25	34	33
Operating Revenue	28	26	48	39	145	31	32	29	25	34	33
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	150	129	153	145	161	122	112	112	111	108	103
Selling, General & Admin Expense	28	28	30	30	32	29	30	28	30	28	26
Research & Development Expense	122	101	123	115	109	93	82	84	81	80	77
Total Other Income / (Expense), net	10	10	13	13	12	11	11	9.00	8.00	7.00	5.00
Interest Expense	1.00	2.00	1.00	0.00	1.00	-	1.00	0.00	1.00	1.00	0.00
Other Income / (Expense), net	11	-	14	13	13	11	12	9.00	9.00	8.00	5.00
Income Tax Expense	0.00	1.00	0.00	0.00	0.00	1.00	2.00	1.00	2.00	-	0.00
Basic Earnings per Share	($1.14)	($1.07)	($1.00)	($1.02)	($0.05)	($1.08)	($0.94)	($1.04)	($1.09)	-	-
Weighted Average Basic Shares Outstanding	98.40M	90.10M	91.40M	91.10M	86.20M	74M	74.60M	73.20M	73M	72M	72.20M
Diluted Earnings per Share	($1.14)	($1.07)	($1.00)	($1.02)	($0.05)	($1.08)	($0.94)	($1.04)	($1.09)	-	-
Weighted Average Diluted Shares Outstanding	98.40M	90.10M	91.40M	91.10M	86.20M	74M	74.60M	73.20M	73M	72M	72.20M
Weighted Average Basic & Diluted Shares Outstanding	105.89M	105.84M	91.51M	91.43M	90.95M	90.86M	74.86M	74.50M	73.11M	73.01M	72.41M

This table details how cash moves in and out of Arcus Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Change in Cash & Equivalents	23	-79	58	-23	116	-13	-27	33	18
Net Cash From Operating Activities	-170	-306	438	-256	111	-73	-43	-25	-13
Net Cash From Continuing Operating Activities	-170	-306	438	-256	111	-73	-43	-25	-13
Net Income / (Loss) Continuing Operations	-283	-307	-267	53	-123	-85	-50	-53	-18
Consolidated Net Income / (Loss)	-283	-307	-267	53	-123	-85	-50	-53	-18
Depreciation Expense	10	8.00	6.00	4.00	3.00	3.58	3.66	2.61	1.31
Amortization Expense	-25	-19	0.00	5.00	0.00	-2.64	-1.75	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	131	96	777	41	22	12	5.32	0.81	0.09
Changes in Operating Assets and Liabilities, net	-3.00	-84	-78	-359	209	-1.50	-0.29	25	3.62
Net Cash From Investing Activities	-84	194	-413	-4.00	-434	59	-113	-49	-39
Net Cash From Continuing Investing Activities	-84	194	-413	-4.00	-434	59	-113	-49	-39
Purchase of Property, Plant & Equipment	-6.00	-24	-6.00	-26	-3.00	-1.93	-3.74	-5.51	-4.10
Purchase of Investments	-1,043	-788	-1,241	-719	-740	-248	-262	-97	-34
Sale and/or Maturity of Investments	965	1,006	837	741	309	309	152	53	0.00
Other Investing Activities, net	0.00	0.00	-3.00	0.00	0.00	-	-	-	-1.00
Net Cash From Financing Activities	277	33	33	237	439	1.12	129	107	70
Net Cash From Continuing Financing Activities	277	33	33	237	439	1.12	129	107	70
Issuance of Debt	47	0.00	0.00	-	-	-	-	-	-
Issuance of Common Equity	237	33	23	232	439	1.22	129	0.89	0.28
Other Financing Activities, net	-7.00	0.00	10	5.00	0.00	-	-	-0.37	0.00
Cash Interest Paid	1.00	0.00	0.00	-	-	-	-	-	-
Cash Income Taxes Paid	0.00	5.00	3.00	0.00	0.00	-	-	-	-

This table details how cash moves in and out of Arcus Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	42	-51	45	-29	58	-57	-46	-8.00	32	-12	-55
Net Cash From Operating Activities	-132	-100	26	-94	-2.00	-88	-63	-57	-98	-70	-81
Net Cash From Continuing Operating Activities	-132	-100	26	-94	-2.00	-88	-63	-57	-98	-70	-81
Net Income / (Loss) Continuing Operations	-112	-94	-92	-93	-4.00	-81	-71	-75	-80	-67	-65
Consolidated Net Income / (Loss)	-112	-94	-92	-93	-4.00	-81	-71	-75	-80	-67	-65
Depreciation Expense	3.00	3.00	2.00	2.00	3.00	3.00	1.00	2.00	2.00	1.00	2.00
Amortization Expense	-4.00	-6.00	-6.00	-7.00	-6.00	-12	1.00	-4.00	-4.00	-2.00	-
Non-Cash Adjustments To Reconcile Net Income	23	15	32	29	55	41	10	18	27	7.00	25
Changes in Operating Assets and Liabilities, net	-42	-18	90	-25	-50	-39	-4.00	2.00	-43	-9.00	-43
Net Cash From Investing Activities	32	51	-29	63	-169	28	11	26	129	47	23
Net Cash From Continuing Investing Activities	32	51	-29	63	-169	28	11	26	129	47	23
Purchase of Property, Plant & Equipment	-1.00	-1.00	-1.00	-	-4.00	-6.00	-10	-5.00	-3.00	-	-2.00
Purchase of Investments	-353	-172	-278	-206	-387	-115	-280	-239	-154	-156	-322
Sale and/or Maturity of Investments	386	224	250	269	222	149	301	270	286	203	344
Net Cash From Financing Activities	142	-2.00	48	2.00	229	3.00	6.00	23	1.00	11	3.00
Net Cash From Continuing Financing Activities	142	-2.00	48	2.00	229	3.00	6.00	23	1.00	11	3.00
Issuance of Common Equity	142	3.00	2.00	3.00	229	3.00	6.00	23	1.00	6.00	3.00

This table presents Arcus Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Total Assets	1,150	1,095	1,345	1,592	772	203	275	190
Total Current Assets	1,016	831	1,067	1,262	736	193	259	177
Cash & Equivalents	150	127	206	148	173	58	71	98
Short-Term Investments	828	632	803	351	555	130	185	77
Prepaid Expenses	18	34	19	18	5.47	4.05	2.32	1.14
Other Current Assets	20	38	39	745	1.05	0.13	0.00	-
Plant, Property, & Equipment, net	47	51	35	32	11	9.33	11	11
Total Noncurrent Assets	87	213	243	298	26	1.08	4.87	2.39
Long-Term Investments	14	107	129	182	6.44	0.00	4.38	0.68
Other Noncurrent Operating Assets	73	106	114	116	19	1.08	0.49	1.71
Total Liabilities & Shareholders' Equity	1,150	1,095	1,345	1,592	772	203	275	190
Total Liabilities	665	633	688	750	270	39	40	37
Total Current Liabilities	226	184	193	166	122	23	17	13
Accounts Payable	18	17	20	10	16	4.70	3.10	3.82
Current Deferred Revenue	85	91	97	102	75	7.00	6.25	5.00
Other Current Liabilities	123	76	76	54	3.57	1.48	1.56	0.77
Total Noncurrent Liabilities	439	449	495	584	148	17	23	24
Long-Term Debt	48	0.00	-	-	-	-	-	-
Noncurrent Deferred Revenue	234	307	355	462	133	16	21	23
Other Noncurrent Operating Liabilities	157	142	140	122	16	0.81	1.79	0.57
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	485	462	657	842	502	164	235	-72
Total Preferred & Common Equity	485	462	657	842	502	164	235	-72
Total Common Equity	485	462	657	842	502	164	235	-72
Common Stock	1,617	1,311	1,206	1,118	830	369	358	0.95
Retained Earnings	-1,132	-849	-542	-275	-328	-205	-123	-73

This table presents Arcus Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,156	1,252	1,186	1,293	1,191	1,220	1,254	1,394
Total Current Assets	1,031	1,127	1,022	1,064	882	986	1,015	1,101
Cash & Equivalents	192	201	156	185	184	230	238	218
Short-Term Investments	805	888	813	810	615	700	716	831
Prepaid Expenses	19	22	25	34	31	22	28	22
Other Current Assets	15	16	28	35	52	34	33	27
Plant, Property, & Equipment, net	46	48	49	51	50	45	37	34
Total Noncurrent Assets	79	77	115	178	259	189	202	259
Long-Term Investments	8.00	2.00	40	100	151	80	90	143
Other Noncurrent Operating Assets	71	75	75	78	108	109	112	116
Total Liabilities & Shareholders' Equity	1,156	1,252	1,186	1,293	1,191	1,220	1,254	1,394
Total Liabilities	625	687	551	586	671	654	654	695
Total Current Liabilities	192	215	199	204	200	180	179	177
Accounts Payable	22	13	15	16	17	12	28	11
Current Deferred Revenue	72	105	113	124	103	103	97	103
Other Current Liabilities	98	97	71	64	80	65	54	2.98
Total Noncurrent Liabilities	433	472	352	382	471	474	475	518
Long-Term Debt	48	47	-	-	-	-	-	-
Noncurrent Deferred Revenue	219	289	214	242	326	330	330	383
Other Noncurrent Operating Liabilities	166	136	138	140	145	144	145	135
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	531	565	635	707	520	566	600	699
Total Preferred & Common Equity	531	565	635	707	520	566	600	699
Total Common Equity	531	565	635	707	520	566	600	699
Common Stock	1,775	1,602	1,582	1,561	1,291	1,267	1,226	1,183
Retained Earnings	-1,244	-1,038	-946	-853	-768	-697	-622	-475

This table displays calculated financial ratios and metrics derived from Arcus Biosciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	120.51%	4.46%	-70.76%	391.03%	420.00%	79.58%	491.15%	0.00%	0.00%
EBITDA Growth	-11.29%	-20.16%	-503.13%	153.33%	-45.33%	-71.93%	4.05%	-196.74%	0.00%
EBIT Growth	-10.37%	-13.26%	-580.00%	144.72%	-47.29%	-67.23%	5.18%	-189.66%	0.00%
NOPAT Growth	2.94%	-21.43%	-476.66%	159.95%	-39.78%	-61.70%	-2.65%	-193.92%	0.00%
Net Income Growth	7.82%	-14.98%	-603.77%	143.09%	-45.20%	-70.81%	6.57%	-195.39%	0.00%
EPS Growth	24.34%	-11.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	44.44%	-169.86%	271.09%	-330.63%	251.10%	-70.86%	-71.58%	-93.60%	0.00%
Free Cash Flow Firm Growth	44.13%	-170.63%	230.51%	-381.15%	290.96%	-82.21%	-134.58%	0.00%	0.00%
Invested Capital Growth	-13.61%	16.01%	-398.76%	169.16%	-852.93%	5.99%	-15.40%	0.00%	0.00%
Revenue Q/Q Growth	-1.90%	-2.50%	-74.11%	898.62%	0.28%	120.20%	3.88%	0.00%	0.00%
EBITDA Q/Q Growth	-19.79%	-7.64%	-374.03%	123.51%	-40.96%	-5.64%	8.23%	0.00%	0.00%
EBIT Q/Q Growth	-23.60%	-4.91%	-416.02%	119.75%	-40.41%	-5.86%	8.74%	0.00%	0.00%
NOPAT Q/Q Growth	-3.77%	-5.26%	-371.12%	126.66%	-38.16%	-4.78%	-0.26%	0.00%	0.00%
Net Income Q/Q Growth	-4.81%	-4.78%	-435.69%	119.03%	-40.41%	-5.35%	1.81%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-7.59%	-6.25%	-1.81%	-4.87%	-26.77%	-3.33%	-111.78%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-1.38%	-8.88%	22.28%	-45.36%	-23.13%	-3.50%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	4.18%	6.05%	2.48%	180.19%	3.30%	-23.66%	-18.18%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
EBITDA Margin	-133.72%	-264.96%	-230.36%	16.71%	-153.85%	-550.45%	-574.94%	-3,542.39%	0.00%
Operating Margin	-127.91%	-290.60%	-250.00%	14.10%	-158.97%	-591.39%	-656.76%	-3,782.09%	0.00%
EBIT Margin	-127.91%	-255.56%	-235.71%	14.36%	-157.69%	-556.72%	-597.83%	-3,727.25%	0.00%
Profit (Net Income) Margin	-109.69%	-262.39%	-238.39%	13.84%	-157.69%	-564.73%	-593.73%	-3,756.69%	0.00%
Tax Burden Percent	100.35%	101.99%	100.38%	96.36%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	85.45%	100.67%	100.76%	100.00%	100.00%	101.44%	99.31%	100.79%	98.83%
Effective Tax Rate	0.00%	0.00%	0.00%	3.64%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-59.77%	-54.87%	-35.62%	7.89%	-36.93%	-42.48%	-25.51%	-34.50%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-212.26%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-29.40%	-24.51%	-17.98%	4.65%	-25.22%	-34.94%	-21.46%	-27.65%	0.00%
Return on Assets (ROA)	-25.21%	-25.16%	-18.18%	4.48%	-25.22%	-35.44%	-21.31%	-27.87%	0.00%
Return on Common Equity (ROCE)	-59.77%	-54.87%	-35.62%	7.89%	-36.93%	-42.48%	-10.67%	16.22%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-58.35%	-66.45%	-40.64%	6.29%	-24.49%	-51.70%	-21.11%	73.39%	0.00%
Net Operating Profit after Tax (NOPAT)	-231	-238	-196	52	-87	-62	-38	-37	-13
NOPAT Margin	-89.53%	-203.42%	-175.00%	13.59%	-111.28%	-413.98%	-459.73%	-2,647.47%	0.00%
Net Nonoperating Expense Percent (NNEP)	-5.75%	-6.89%	-7.81%	0.14%	-7.84%	-10.07%	-5.12%	-17.77%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-43.34%	-51.52%	-29.83%	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	46.51%	100.00%	92.86%	18.80%	55.13%	168.19%	162.41%	540.41%	0.00%
R&D to Revenue	173.64%	290.60%	257.14%	67.10%	203.85%	523.21%	594.35%	3,341.68%	0.00%
Operating Expenses to Revenue	227.91%	390.60%	350.00%	85.90%	258.97%	691.39%	756.76%	3,882.09%	0.00%
Earnings before Interest and Taxes (EBIT)	-330	-299	-264	55	-123	-84	-50	-53	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-345	-310	-258	64	-120	-83	-48	-50	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.81	3.09	2.28	3.38	3.36	2.83	2.04	0.00	0.00
Price to Tangible Book Value (P/TBV)	2.81	3.09	2.28	3.38	3.36	2.83	2.04	0.00	0.00
Price to Revenue (P/Rev)	5.28	12.22	13.37	7.42	21.61	30.88	57.32	84.93	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	53.64	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	1.86%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	13.43	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.62	4.82	3.21	5.64	12.18	18.33	26.08	120.18	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	33.78	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	39.31	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	41.55	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.82	0.00	8.56	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.81	0.00	7.82	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.91	-1.79	-1.21	-1.05	-1.39	-1.13	-1.12	-1.15	0.00
Leverage Ratio	2.37	2.18	1.96	1.76	1.46	1.20	1.20	1.24	0.00
Compound Leverage Factor	2.03	2.20	1.97	1.76	1.46	1.22	1.19	1.25	0.00
Debt to Total Capital	9.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	9.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	147.01%	0.00%
Common Equity to Total Capital	90.99%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-47.01%	0.00%
Debt to EBITDA	-0.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	2.74	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	4.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.05	0.18	0.96	3.21	3.68	5.38	7.05	1.56	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	58.18%	147.01%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	4.50	4.52	5.53	7.60	6.05	8.49	15.29	13.90	0.00
Quick Ratio	4.33	4.13	5.23	3.01	5.99	8.30	15.15	13.81	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-176	-315	446	-342	122	-64	-35	-15	0.00
Operating Cash Flow to CapEx	-2,833.33%	-1,275.00%	7,300.00%	-984.62%	3,700.00%	-3,816.21%	-1,148.70%	-454.46%	-315.78%
Free Cash Flow to Firm to Interest Expense	-44.00	-157.50	223.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-42.50	-153.00	219.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-44.00	-165.00	216.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.23	0.10	0.08	0.32	0.16	0.06	0.04	0.01	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	154.69	56.52	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	5.27	2.72	3.34	17.89	7.75	1.47	0.75	0.13	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	2.36	6.46	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	2.36	6.46	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	-459	-404	-481	161	-233	-24	-26	-23	0.00
Invested Capital Turnover	-0.60	-0.26	-0.70	-10.67	-0.61	-0.60	-0.34	-0.13	0.00
Increase / (Decrease) in Invested Capital	-55	77	-642	394	-208	1.56	-3.47	-23	0.00
Enterprise Value (EV)	419	564	359	2,162	950	275	218	170	0.00
Market Capitalization	1,363	1,430	1,497	2,843	1,685	463	479	120	120
Book Value per Share	$5.30	$6.17	$9.07	$11.99	$7.74	$3.57	$5.29	($39.56)	$0.00
Tangible Book Value per Share	$5.30	$6.17	$9.07	$11.99	$7.74	$3.57	$5.29	($39.56)	$0.00
Total Capital	533	462	657	842	502	164	235	154	0.00
Total Debt	48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-944	-866	-1,138	-681	-735	-188	-261	-176	0.00
Capital Expenditures (CapEx)	6.00	24	6.00	26	3.00	1.93	3.74	5.51	4.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-188	-112	-135	597	-115	-18	-15	-12	0.00
Debt-free Net Working Capital (DFNWC)	790	647	874	1,096	614	170	242	164	0.00
Net Working Capital (NWC)	790	647	874	1,096	614	170	242	164	0.00
Net Nonoperating Expense (NNE)	52	69	71	-0.96	36	23	11	16	5.24
Net Nonoperating Obligations (NNO)	-944	-866	-1,138	-681	-735	-188	-261	-176	0.00
Total Depreciation and Amortization (D&A)	-15	-11	6.00	9.00	3.00	0.94	1.91	2.61	1.31
Debt-free, Cash-free Net Working Capital to Revenue	-72.87%	-95.73%	-120.54%	155.87%	-146.79%	-121.81%	-173.96%	-818.12%	0.00%
Debt-free Net Working Capital to Revenue	306.20%	552.99%	780.36%	286.16%	787.37%	1,133.33%	2,897.32%	11,616.63%	0.00%
Net Working Capital to Revenue	306.20%	552.99%	780.36%	286.16%	787.37%	1,133.33%	2,897.32%	11,616.63%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.14)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	90.10M	74M	72M	69.35M	70.88M	45.97M	44.53M	0.00	0.00
Adjusted Diluted Earnings per Share	($3.14)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	90.10M	74M	72M	73.97M	70.88M	45.97M	44.53M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	105.84M	90.86M	73.01M	71.06M	54.79M	43.83M	34.62M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-217	-238	-196	52	-87	-62	-38	-37	-13
Normalized NOPAT Margin	-84.11%	-203.42%	-175.00%	13.59%	-111.28%	-413.98%	-459.73%	-2,647.47%	0.00%
Pre Tax Income Margin	-109.30%	-257.27%	-237.50%	14.36%	-157.69%	-564.73%	-593.73%	-3,756.69%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-82.50	-149.50	-132.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-57.75	-119.00	-98.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-84.00	-161.50	-135.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-59.25	-131.00	-101.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.27%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Arcus Biosciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-80.69%	-16.13%	50.00%	34.48%	480.00%	-8.82%	-3.03%	7.41%	38.89%	-90.41%	248.80%
EBITDA Growth	-489.47%	-19.10%	-43.94%	-28.95%	92.41%	-32.84%	-4.76%	-18.75%	-23.44%	-123.50%	16.69%
EBIT Growth	-593.75%	-28.75%	-33.82%	-25.68%	96.10%	-21.21%	-4.62%	-12.12%	-14.93%	-123.44%	16.64%
NOPAT Growth	-662.50%	-13.19%	-31.25%	-27.71%	81.40%	-22.97%	-14.29%	-20.29%	-28.36%	-118.56%	10.41%
Net Income Growth	-2,700.00%	-16.05%	-29.58%	-24.00%	95.00%	-20.90%	-9.23%	-11.94%	-17.65%	-123.97%	16.64%
EPS Growth	-2,180.00%	0.93%	-6.38%	1.92%	95.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-6,500.00%	-13.64%	141.27%	-64.91%	97.96%	-25.71%	22.22%	12.31%	-114.98%	-13.03%	-50.68%
Free Cash Flow Firm Growth	29.46%	87.85%	79.45%	-4.63%	58.52%	-123.84%	-148.97%	-150.14%	-158.11%	614.29%	357.23%
Invested Capital Growth	-9.79%	-13.61%	-11.40%	15.77%	12.61%	16.01%	12.82%	15.22%	18.65%	-398.76%	-145.67%
Revenue Q/Q Growth	7.69%	-45.83%	23.08%	-73.10%	367.74%	-3.13%	10.34%	16.00%	-26.47%	3.03%	22.22%
EBITDA Q/Q Growth	-5.66%	-11.58%	3.06%	-1,533.33%	92.77%	-34.85%	13.16%	3.80%	-17.91%	-6.35%	1.56%
EBIT Q/Q Growth	-7.77%	-13.19%	2.15%	-3,000.00%	96.25%	-17.65%	8.11%	3.90%	-16.67%	-1.54%	1.52%
NOPAT Q/Q Growth	-18.45%	1.90%	0.94%	-562.50%	82.42%	-13.75%	3.61%	3.49%	-16.22%	-5.71%	-1.45%
Net Income Q/Q Growth	-19.15%	-2.17%	1.08%	-2,225.00%	95.06%	-14.08%	5.33%	6.25%	-19.40%	-3.08%	2.99%
EPS Q/Q Growth	-6.54%	-7.00%	1.96%	-1,940.00%	0.00%	-14.89%	9.62%	4.59%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-32.00%	-484.62%	127.66%	-4,600.00%	97.73%	-39.68%	-10.53%	41.84%	-40.00%	13.58%	-24.62%
Free Cash Flow Firm Q/Q Growth	-177.19%	30.20%	83.01%	-114.58%	52.24%	-18.02%	13.50%	14.92%	-127.45%	142.43%	-11.43%
Invested Capital Q/Q Growth	7.19%	4.18%	-28.07%	3.61%	3.96%	6.05%	3.15%	0.00%	7.69%	2.48%	5.82%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-400.00%	-407.69%	-197.92%	-251.28%	-4.14%	-287.10%	-206.25%	-262.07%	-316.00%	-197.06%	-190.91%
Operating Margin	-435.71%	-396.15%	-218.75%	-271.79%	-11.03%	-293.55%	-250.00%	-286.21%	-344.00%	-217.65%	-212.12%
EBIT Margin	-396.43%	-396.15%	-189.58%	-238.46%	-2.07%	-258.06%	-212.50%	-255.17%	-308.00%	-194.12%	-196.97%
Profit (Net Income) Margin	-400.00%	-361.54%	-191.67%	-238.46%	-2.76%	-261.29%	-221.88%	-258.62%	-320.00%	-197.06%	-196.97%
Tax Burden Percent	100.00%	101.08%	100.00%	100.00%	100.00%	101.25%	102.90%	101.35%	102.56%	100.00%	100.00%
Interest Burden Percent	100.90%	90.29%	101.10%	100.00%	133.33%	100.00%	101.47%	100.00%	101.30%	101.52%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-63.17%	-59.77%	-49.77%	-41.47%	-35.35%	-54.87%	-48.08%	-43.70%	-39.95%	-35.62%	12.82%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-45.65%	-91.05%	-40.82%	-48.96%	-0.39%	-24.75%	-19.73%	-22.90%	-26.20%	-14.81%	-76.32%
Return on Assets (ROA)	-46.06%	-83.10%	-41.27%	-48.96%	-0.51%	-25.06%	-20.60%	-23.21%	-27.23%	-15.03%	-76.32%
Return on Common Equity (ROCE)	-63.17%	-59.77%	-49.77%	-41.47%	-35.35%	-54.87%	-48.08%	-43.70%	-39.95%	-35.62%	12.82%
Return on Equity Simple (ROE_SIMPLE)	-73.63%	0.00%	-47.79%	-39.21%	-32.67%	0.00%	-56.35%	-50.71%	-46.50%	0.00%	11.38%
Net Operating Profit after Tax (NOPAT)	-85	-72	-74	-74	-11	-64	-56	-58	-60	-52	-49
NOPAT Margin	-305.00%	-277.31%	-153.13%	-190.26%	-7.72%	-205.48%	-175.00%	-200.34%	-240.80%	-152.35%	-148.48%
Net Nonoperating Expense Percent (NNEP)	-2.59%	-2.42%	-1.86%	-1.86%	0.67%	-1.73%	-1.40%	-1.48%	-1.66%	-1.67%	-1.65%
Return On Investment Capital (ROIC_SIMPLE)	-14.75%	-13.53%	-	-	-	-13.79%	-	-	-	-7.88%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	100.00%	107.69%	62.50%	76.92%	22.07%	93.55%	93.75%	96.55%	120.00%	82.35%	78.79%
R&D to Revenue	435.71%	388.46%	256.25%	294.87%	75.17%	300.00%	256.25%	289.66%	324.00%	235.29%	233.33%
Operating Expenses to Revenue	535.71%	496.15%	318.75%	371.79%	111.03%	393.55%	350.00%	386.21%	444.00%	317.65%	312.12%
Earnings before Interest and Taxes (EBIT)	-111	-103	-91	-93	-3.00	-80	-68	-74	-77	-66	-65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-112	-106	-95	-98	-6.00	-89	-66	-76	-79	-67	-63
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.56	2.81	2.47	2.18	2.00	3.09	2.57	2.62	2.22	2.28	2.70
Price to Tangible Book Value (P/TBV)	1.56	2.81	2.47	2.18	2.00	3.09	2.57	2.62	2.22	2.28	2.70
Price to Revenue (P/Rev)	5.89	5.28	5.32	5.61	5.96	12.22	11.14	12.27	11.19	13.37	4.36
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	23.72
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.22%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	1.62	1.35	1.52	1.34	4.82	3.23	3.92	2.42	3.21	1.61
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.39
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.33
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.62
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.82	1.56
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	1.91
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.09	0.10	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.09	0.10	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.66	-1.91	-1.84	-1.68	-1.64	-1.79	-1.76	-1.74	-1.71	-1.21	-1.56
Leverage Ratio	1.98	2.37	2.25	2.00	1.95	2.18	2.12	2.05	2.00	1.96	1.80
Compound Leverage Factor	2.00	2.14	2.28	2.00	2.60	2.18	2.15	2.05	2.03	1.99	1.80
Debt to Total Capital	8.29%	9.01%	7.68%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.29%	9.01%	7.68%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.71%	90.99%	92.32%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.11	-0.14	-0.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	2.13	2.74	3.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.11	-0.14	-0.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.16	-0.21	-0.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	3.14	4.09	4.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.16	-0.21	-0.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.03	0.60	0.90	1.17	1.50	0.84	0.89	1.25	1.22	1.44	2.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.37	4.50	5.24	5.14	5.22	4.52	4.41	5.48	5.67	5.53	6.21
Quick Ratio	5.19	4.33	5.07	4.87	4.88	4.13	4.00	5.17	5.33	5.23	5.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-47	-17	-25	-144	-67	-141	-119	-138	-162	590	243
Operating Cash Flow to CapEx	-13,200.00%	-10,000.00%	2,600.00%	0.00%	-50.00%	-1,466.67%	-630.00%	-1,140.00%	-3,266.67%	0.00%	-4,050.00%
Free Cash Flow to Firm to Interest Expense	-47.40	-8.55	-24.50	0.00	-67.20	0.00	-119.22	0.00	-161.99	590.20	0.00
Operating Cash Flow to Interest Expense	-132.00	-50.00	26.00	0.00	-2.00	0.00	-63.00	0.00	-98.00	-70.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-133.00	-50.50	25.00	0.00	-6.00	0.00	-73.00	0.00	-101.00	-70.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.12	0.23	0.22	0.21	0.19	0.10	0.09	0.09	0.09	0.08	0.39
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.91	5.27	5.37	5.26	5.39	2.72	2.86	3.09	3.38	3.34	13.80
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-426	-459	-479	-374	-388	-404	-430	-444	-444	-481	-493
Invested Capital Turnover	-0.35	-0.60	-0.58	-0.60	-0.57	-0.26	-0.26	-0.25	-0.24	-0.70	-1.25
Increase / (Decrease) in Invested Capital	-38	-55	-49	70	56	77	63	80	102	-642	-292
Enterprise Value (EV)	-126	419	354	376	318	564	387	475	288	359	696
Market Capitalization	831	1,363	1,398	1,385	1,413	1,430	1,337	1,485	1,332	1,497	1,888
Book Value per Share	$5.02	$5.30	$6.18	$6.98	$8.20	$6.17	$6.98	$7.74	$8.22	$9.07	$9.68
Tangible Book Value per Share	$5.02	$5.30	$6.18	$6.98	$8.20	$6.17	$6.98	$7.74	$8.22	$9.07	$9.68
Total Capital	579	533	612	635	707	462	520	566	600	657	699
Total Debt	48	48	47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	48	48	47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-957	-944	-1,044	-1,009	-1,095	-866	-950	-1,010	-1,044	-1,138	-1,192
Capital Expenditures (CapEx)	1.00	1.00	1.00	0.00	4.00	6.00	10	5.00	3.00	0.00	2.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-158	-188	-177	-146	-135	-112	-117	-124	-118	-135	-125
Debt-free Net Working Capital (DFNWC)	839	790	912	823	860	647	682	806	836	874	924
Net Working Capital (NWC)	839	790	912	823	860	647	682	806	836	874	924
Net Nonoperating Expense (NNE)	27	22	19	19	-7.20	17	15	17	20	15	16
Net Nonoperating Obligations (NNO)	-957	-944	-1,044	-1,009	-1,095	-866	-950	-1,010	-1,044	-1,138	-1,192
Total Depreciation and Amortization (D&A)	-1.00	-3.00	-4.00	-5.00	-3.00	-9.00	2.00	-2.00	-2.00	-1.00	2.00
Debt-free, Cash-free Net Working Capital to Revenue	-112.06%	-72.87%	-67.30%	-59.11%	-56.96%	-95.73%	-97.50%	-102.48%	-99.16%	-120.54%	-28.86%
Debt-free Net Working Capital to Revenue	595.04%	306.20%	346.77%	333.20%	362.87%	552.99%	568.33%	666.12%	702.52%	780.36%	213.57%
Net Working Capital to Revenue	595.04%	306.20%	346.77%	333.20%	362.87%	552.99%	568.33%	666.12%	702.52%	780.36%	213.57%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.14)	($1.07)	($1.00)	($1.02)	($0.05)	($1.08)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	98.40M	90.10M	91.40M	91.10M	86.20M	74M	74.60M	73.20M	73M	72M	72.24M
Adjusted Diluted Earnings per Share	($1.14)	($1.07)	($1.00)	($1.02)	($0.05)	($1.08)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	98.40M	90.10M	91.40M	91.10M	86.20M	74M	74.60M	73.20M	73M	72M	72.24M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	105.89M	105.84M	91.51M	91.43M	90.95M	90.86M	74.86M	74.50M	73.11M	73.01M	72.41M
Normalized Net Operating Profit after Tax (NOPAT)	-85	-72	-74	-74	2.80	-64	-56	-58	-60	-52	-49
Normalized NOPAT Margin	-305.00%	-277.31%	-153.13%	-190.26%	1.93%	-205.48%	-175.00%	-200.34%	-240.80%	-152.35%	-148.48%
Pre Tax Income Margin	-400.00%	-357.69%	-191.67%	-238.46%	-2.76%	-258.06%	-215.63%	-255.17%	-312.00%	-197.06%	-196.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-111.00	-51.50	-91.00	0.00	-3.00	0.00	-68.00	0.00	-77.00	-66.00	0.00
NOPAT to Interest Expense	-85.40	-36.05	-73.50	0.00	-11.20	0.00	-56.00	0.00	-60.20	-51.80	0.00
EBIT Less CapEx to Interest Expense	-112.00	-52.00	-92.00	0.00	-7.00	0.00	-78.00	0.00	-80.00	-66.00	0.00
NOPAT Less CapEx to Interest Expense	-86.40	-36.55	-74.50	0.00	-15.20	0.00	-66.00	0.00	-63.20	-51.80	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Arcus Biosciences' Financials

When does Arcus Biosciences's fiscal year end?

According to the most recent income statement we have on file, Arcus Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Arcus Biosciences' net income changed over the last 8 years?

Arcus Biosciences' net income appears to be on an upward trend, with a most recent value of -$283 million in 2024, rising from -$17.97 million in 2016. The previous period was -$307 million in 2023. Find out what analysts predict for Arcus Biosciences in the coming months.

What is Arcus Biosciences's operating income?

Arcus Biosciences's total operating income in 2024 was -$330 million, based on the following breakdown:

Total Gross Profit: $258 million
Total Operating Expenses: $588 million

How has Arcus Biosciences revenue changed over the last 8 years?

Over the last 8 years, Arcus Biosciences' total revenue changed from $0.00 in 2016 to $258 million in 2024, a change of 25,800,000,000.0%.

How much debt does Arcus Biosciences have?

Arcus Biosciences' total liabilities were at $665 million at the end of 2024, a 5.1% increase from 2023, and a 1,716.0% increase since 2017.

How much cash does Arcus Biosciences have?

In the past 7 years, Arcus Biosciences' cash and equivalents has ranged from $57.94 million in 2019 to $206 million in 2022, and is currently $150 million as of their latest financial filing in 2024.

How has Arcus Biosciences' book value per share changed over the last 8 years?

Over the last 8 years, Arcus Biosciences' book value per share changed from 0.00 in 2016 to 5.30 in 2024, a change of 530.0%.

Related Companies

This page (NYSE:RCUS) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Financials

Frequently Asked Questions About Arcus Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Financials

Annual Income Statements for Arcus Biosciences

Quarterly Income Statements for Arcus Biosciences

Annual Cash Flow Statements for Arcus Biosciences

Quarterly Cash Flow Statements for Arcus Biosciences

Annual Balance Sheets for Arcus Biosciences

Quarterly Balance Sheets for Arcus Biosciences

Annual Metrics And Ratios for Arcus Biosciences

Quarterly Metrics And Ratios for Arcus Biosciences

Frequently Asked Questions About Arcus Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools